1.Effective Timing of Introducing an Inpatient Smoking Cessation Program to Cancer Patients
Yu-Ri CHOE ; Ji-Won CHOI ; Ju-Ri JEONG ; Hye-Mi DOH ; Mi-Lee KIM ; Min-Seol NAM ; Hee-Ji KHO ; Ha-Young PARK ; Hye-Ran AHN ; Sun-Seog KWEON ; Yu-Il KIM ; In-Jae OH
Yonsei Medical Journal 2023;64(4):251-258
Purpose:
We aimed to identify factors influencing smoking cessation success among cancer patients registered in an inpatient smoking cessation program at a single cancer center.
Materials and Methods:
The electronic medical records of enrolled patients with solid cancer were retrospectively reviewed. We evaluated factors associated with 6-month smoking cessation.
Results:
A total of 458 patients with cancer were included in this study. Their mean age was 62.9±10.3 years, and 56.3% of the participants had lung cancer. 193 (42.1%) had not yet begun their main treatment. The mean number of counseling sessions for the participants was 8.4±3.5, and 46 (10.0%) patients were prescribed smoking cessation medications. The 6-month smoking cessation success rate was 48.0%. Multivariate analysis showed that younger age (<65 years), cohabited status, early stage, and the number of counseling sessions were statistically significant factors affecting 6-month smoking cessation success (p<0.05). Initiation of a cessation program before cancer treatment was significantly associated with cessation success (odds ratio, 1.66; 95% confidence interval, 1.02–2.70; p=0.040).
Conclusion
Smoking cessation intervention must be considered when establishing a treatment plan immediately after a cancer diagnosis among smokers.
2.Evaluation of Clinical Outcomes by Therapeutic Dosing Interval of Denosumab (Prolia ® ) and Calcium-Vitamin D Prescriptions
Youkyeong KIM ; Junghyun KIM ; Hyunjeong DOH ; Young Mi JEONG ; Jeonghwa LEE ; Ju-Yeun LEE ; Euni LEE
Korean Journal of Clinical Pharmacy 2022;32(3):185-190
Background:
Denosumab (Prolia®) is administered every 6 months for osteoporosis treatment. Co-administration of calcium and vitamin D is required to minimize hypocalcemia risk. We evaluated clinical outcomes based on the administration interval of denosumab and co-prescription with calcium-vitamin D combination products.
Methods:
A retrospective study was conducted using electronic medical records from 668 patients who started denosumab therapy between January 1 and December 31, 2018, at Seoul National University Bundang Hospital. Clinical outcomes, as measured by changes in T-score, were evaluated by the intervals and concurrent prescriptions with calcium–vitamin D combination products.
Results:
Of the 668 patients, 333 patients met the eligibility criteria. These patients were divided into two groups based on appropriateness of the administration interval: “Appropriate” (304 patients, 91.3%) and “Inappropriate” (29 patients, 8.3%). T-score changes were significantly higher in the “Appropriate” than in the “Inappropriate” group (0.30±0.44 vs. 0.13±0.37, p=0.048). At the beginning of the treatment, 221 patients (66.4%) were prescribed calcium-vitamin D combination products, but the changes in T-scores were not significantly different by the prescription status of the product (0.29±0.46 vs. 0.28±0.38, p=0.919).
Conclusion
T-scores were significantly improved in patients with appropriate administration intervals. No significant changes in T-scores were observed by the prescription status with calcium-vitamin D combination products. For optimal treatment outcomes, prescribers should encourage adherence to the approved prescription information on dosage and administration, and pharmacists should provide medication counseling for patients.
3.Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery
Young hoon JOO ; Jae keun CHO ; Bon seok KOO ; Minsu KWON ; Seong keun KWON ; Soon young KWON ; Min su KIM ; Jeong kyu KIM ; Heejin KIM ; Innchul NAM ; Jong lyel ROH ; Young min PARK ; Il seok PARK ; Jung je PARK ; Sung chan SHIN ; Soon hyun AHN ; Seongjun WON ; Chang hwan RYU ; Tae mi YOON ; Giljoon LEE ; Doh young LEE ; Myung chul LEE ; Joon kyoo LEE ; Jin choon LEE ; Jae yol LIM ; Jae won CHANG ; Jeon yeob JANG ; Man ki CHUNG ; Yuh seok JUNG ; Jae gu CHO ; Yoon seok CHOI ; Jeong seok CHOI ; Guk haeng LEE ; Phil sang CHUNG
Clinical and Experimental Otorhinolaryngology 2019;12(2):107-144
Korean Society of Thyroid-Head and Neck Surgery appointed a Task Force to provide guidance on the implementation of a surgical treatment of oral cancer. MEDLINE databases were searched for articles on subjects related to “surgical management of oral cancer” published in English. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. The quality of evidence was rated with use RoBANS (Risk of Bias Assessment Tool for Nonrandomized Studies) and AMSTAR (A Measurement Tool to Assess the Methodological Quality of Systematic Reviews). Evidence-based recommendations for practice were ranked according to the American College of Physicians grading system. Additional directives are provided as expert opinions and Delphi questionnaire when insufficient evidence existed. The Committee developed 68 evidence-based recommendations in 34 categories intended to assist clinicians and patients and counselors, and health policy-makers. Proper surgical treatment selection for oral cancer, which is directed by patient- and subsite-specific factors, remains the greatest predictor of successful treatment outcomes. These guidelines are intended for use in conjunction with the individual patient's treatment goals.
Advisory Committees
;
Bias (Epidemiology)
;
Carcinoma, Squamous Cell
;
Counseling
;
Expert Testimony
;
Humans
;
Mouth Neoplasms
;
Neck
;
Republic of Korea
4.Multicenter questionnaires on the current management of atopic dermatitis in Korea.
Dong Hun LEE ; Eun Jin DOH ; Jin Young LEE ; Yang PARK ; Jae Won OH ; Mi Hee LEE ; Soo Jong HONG ; So Yeon LEE ; Joon Soo PARK ; Dong Ho NAHM ; Hye Yung YUM
Allergy, Asthma & Respiratory Disease 2016;4(4):271-275
PURPOSE: The effective management of atopic dermatitis (AD) adjusted to individual clinical courses and demands can be challenging to both patients and physicians. Understanding of actual situations, experienced and perceived by patients with AD and their caregivers, is essential to improve clinical outcomes and satisfaction in real practice. METHODS: This multicenter survey was conducted in patients with AD or their caregivers from 9 centers with questionnaires on diagnosis and management of AD. RESULTS: A total of 324 patients and caregivers participated in the study. Most of the AD cases were initially diagnosed by physicians (80.6%), followed by self-diagnosis. Patients and caregivers thought that allergic substances, such as house dust mites, food, and pollutants, are responsible for AD development; moisturization, environmental control, and improvement of the body constitution are important for AD management. Allergy tests were performed in 194 patients (59.9%), but allergen avoidance strategy was instructed in only 81 subjects (41.8%). Major topical medications were steroids (81.8%) and topical immunomodulators (34.3%), while systemic medications were steroids (42.6%), antihistamines (36.4%), and cyclosporins (2.8%). One hundred eighty-one subjects (55.9%) had received complementary alternative medicine, including Oriental medicine. Many subjects desired to receive individualized management, use of specialized institutions for AD as well as evidence-based, effective, sustainable treatment. CONCLUSION: Our findings suggest that there may still be an unmet need for patients with AD in real practice. Personalized, evidencebased, and multidisciplinary approaches, including patient education, should be implemented for good outcomes.
Body Constitution
;
Caregivers
;
Complementary Therapies
;
Cyclosporine
;
Cyclosporins
;
Dermatitis, Atopic*
;
Diagnosis
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Immunologic Factors
;
Korea*
;
Medicine, East Asian Traditional
;
Patient Education as Topic
;
Pyroglyphidae
;
Steroids
5.Profiling of Proteins Regulated by Venlafaxine during Neural Differentiation of Human Cells.
Mi Sook DOH ; Dal Mu Ri HAN ; Dong Hoon OH ; Seok Hyeon KIM ; Mi Ran CHOI ; Young Gyu CHAI
Psychiatry Investigation 2015;12(1):81-91
OBJECTIVE: Antidepressants are known to positively influence several factors in patients with depressive disorders, resulting in increased neurogenesis and subsequent relief of depressive disorders. To study the effects of venlafaxine during neural differentiation at the cellular level, we looked at its effect on protein expression and regulation mechanisms during neural differentiation. METHODS: After exposing NCCIT cell-derived EBs to venlafaxine during differentiation (1 day and 7 days), changes in protein expression were analyzed by 2-DE and MALDI-TOF MS analysis. Gene levels of proteins regulated by venlafaxine were analyzed by real-time RT-PCR. RESULTS: Treatment with venlafaxine decreased expression of prolyl 4-hydroxylase (P4HB), ubiquitin-conjugating enzyme E2K (HIP2) and plastin 3 (T-plastin), and up-regulated expression of growth factor beta-3 (TGF-beta3), dihydropyrimidinase-like 3 (DPYSL3), and pyruvate kinase (PKM) after differentiation for 1 and 7 days. In cells exposed to venlafaxine, the mRNA expression patterns of HIP2 and PKM, which function as negative and positive regulators of differentiation and neuronal survival, respectively, were consistent with the observed changes in protein expression. CONCLUSION: Our findings may contribute to improve understanding of molecular mechanism of venlafaxine.
Antidepressive Agents
;
Depression
;
Depressive Disorder
;
Humans
;
Neurogenesis
;
Neurons
;
Prolyl Hydroxylases
;
Proteomics
;
Pyruvate Kinase
;
RNA, Messenger
;
Venlafaxine Hydrochloride
6.Effect of Peritoneal Dialysis Modality on the 1-Year Rate of Decline of Residual Renal Function.
Chan Ho KIM ; Hyung Jung OH ; Mi Jung LEE ; Young Eun KWON ; Yung Ly KIM ; Ki Heon NAM ; Kyoung Sook PARK ; Seong Yeong AN ; Kwang Il KO ; Hyang Mo KOO ; Fa Mee DOH ; Seung Hyeok HAN ; Tae Hyun YOO ; Beom Seok KIM ; Shin Wook KANG ; Kyu Hun CHOI
Yonsei Medical Journal 2014;55(1):141-148
PURPOSE: The effect of different peritoneal dialysis (PD) modalities on the decline in residual renal function (RRF) is unclear due to inconsistencies among studies. In particular, the effect of automated peritoneal dialysis (APD) modalities [continuous cyclic peritoneal dialysis (CCPD) and nightly intermittent peritoneal dialysis (NIPD)] on RRF has not been examined in a large cohort. MATERIALS AND METHODS: We conducted a single-center retrospective study to investigate the association between PD modalities and decline in RRF in 142 incident PD patients [34 on CCPD, 36 on NIPD, and 72 on continuous ambulatory peritoneal dialysis (CAPD)]. RRF was measured within 2 months from PD start and at 1 year after PD initiation. RESULTS: The RRF at 1 year after PD initiation was 1.98+/-2.20 mL/min/1.73 m2 in CCPD patients and 3.63+/-3.67 mL/min/1.73 m2 in NIPD patients, which were moderately lower than 4.23+/-3.51 mL/min/1.73 m2 in CAPD patients (p=0.064). Moreover, there was no significant difference in the 1-year rate of decline of RRF between CCPD and NIPD patients, although APD patients had a faster 1-year RRF decline rate than CAPD patients (CCPD and NIPD vs. CAPD: -45.68 and -36.69 vs. 1.17%/year, p=0.045). APD was associated with a more rapid decline in RRF in patients with end-stage renal disease undergoing PD, although multivariate analysis attenuated the significance of this finding (beta=-31.50; 95% CI, -63.61 to 0.62; p=0.052). CONCLUSION: Our results suggest that CAPD might be more helpful than APD for preserving RRF during the first year of dialysis therapy, although there was no significant difference in the 1-year rate of decline of RRF between the two APD modalities.
Adult
;
Female
;
Glomerular Filtration Rate/physiology
;
Humans
;
Kidney/pathology/physiopathology
;
Kidney Failure, Chronic/*therapy
;
Male
;
Middle Aged
;
Peritoneal Dialysis/*adverse effects
;
Retrospective Studies
7.An Unusual Case of Superior Vena Cava Syndrome Caused by the Intravascular Invasion of an Invasive Thymoma.
Hyung Joon KIM ; Sun Young CHO ; Woo Hee CHO ; Do Hyun LEE ; Do Hyoung LIM ; Pil Won SEO ; Mi Hyun PARK ; Wonae LEE ; Jai Hyuen LEE ; Doh Hyung KIM
Tuberculosis and Respiratory Diseases 2013;75(5):210-213
Superior vena cava syndrome (SVCS) is usually caused by extrinsic compression or invasion of the superior vena cava (SVC) by malignant tumors involving mediastinal structures. Although thymomas are well-known causes of SVCS, cases of SVCS caused by malignant thymomas protruding into adjacent vessels draining the SVC with thrombosis have been very rarely reported worldwide. We experienced a 39-year-old female patient with SVCS that developed after the direct invasion of the left brachiocephalic vein (LBCV) and SVC by an anterior mediastinal mass with a high maximum standardized uptake value on the chest computed tomography (CT) and positron emission tomography-CT. Based on these results, she underwent en bloc resection of the tumor, including removal of the involved vessels, and was eventually diagnosed as having a type B2 thymoma permeating into the LBCV and SVC. We present this case as a very rare form of SVCS caused by an invasive thymoma.
Adult
;
Brachiocephalic Veins
;
Electrons
;
Female
;
Humans
;
Positron-Emission Tomography
;
Superior Vena Cava Syndrome*
;
Thorax
;
Thrombosis
;
Thymoma*
;
Vena Cava, Superior*
8.A case of transfusion-related acute lung injury induced by anti-human leukocyte antigen antibodies in acute leukemia.
Sun Mi JIN ; Moon Ju JANG ; Ji Young HUH ; Myoung Hee PARK ; Eun Young SONG ; Doyeun OH
Korean Journal of Hematology 2012;47(4):302-306
Transfusion-related acute lung injury (TRALI) is a noncardiogenic pulmonary edema that occurs during or within 6 hours after transfusion. Risk factors for TRALI, which is relatively common in critically ill patients, include recent surgery, hematologic malignancy, and sepsis. Here, we report a case of TRALI induced by anti-human leukocyte antigen (anti-HLA) class II antibodies (HLA-DR) occurring after transfusion of platelet concentrates in a patient with acute leukemia. Although most patients with TRALI show improvement within 48-96 hours, our patient's condition rapidly worsened, and he did not respond to supportive treatment. TRALI is a relatively common and serious adverse transfusion reaction that requires prompt diagnosis and management.
Acute Lung Injury
;
Antibodies
;
Blood Group Incompatibility
;
Blood Platelets
;
Critical Illness
;
Hematologic Neoplasms
;
Humans
;
Leukemia
;
Leukocytes
;
Pulmonary Edema
;
Risk Factors
;
Sepsis
9.A Case of Wernicke's Encephalopathy Occurring in a Patient with Aspiration Pneumonia: A Case Report.
So Mi KIM ; Ji Hyun SUH ; Ran NOH ; Young Kwang CHOO ; Sung Soo LA ; Jae Seuk PARK ; Doh Hyung KIM
The Korean Journal of Critical Care Medicine 2008;23(2):106-110
Wernicke's encephalopathy is a neurologic complication of thiamine deficiency, presenting with acute confusion, oculomotor dysfunction, and gait ataxia. While most often associated with chronic alcoholism, Wernicke's encephalopathy occasionally occurs in the setting of poor nutritional status, such as malabsorption, increased metabolic requirements, or increased loss of the water-soluble vitamins. Patients with critical illnesses can present with excessive catabolic status because of activation of the sympathetic nervous system and the pituitary-adrenal axis. In addition, inappropriate nutritional evaluation and lack of concerns for adequate nutrient support can increase the morbidity and mortality in such patients. However, the importance of adequate nutritional support is often disregarded during treatment of the patient's primary illness. We have recently managed a patient with Wernicke's encephalopathy and pneumonia who did not receive adequate nutritional support during hospitalization. We report this case to call attention to the importance of nutritional support in critically ill patients.
Alcoholism
;
Axis, Cervical Vertebra
;
Critical Illness
;
Gait Ataxia
;
Hospitalization
;
Humans
;
Nutritional Status
;
Nutritional Support
;
Pneumonia
;
Sympathetic Nervous System
;
Thiamine Deficiency
;
Vitamins
;
Wernicke Encephalopathy
10.Two Cases of Primary Sjogren's Syndrome Presenting as Relapsing-Remitting Multiple Sclerosis.
Jeong Hee CHO ; Seung Min KIM ; Jee Heun KIM ; Chong Kyu CHU ; Mi Hee LEE ; Hae Won SHIN ; Won Young DOH ; Il Nam SUNWOO
Journal of the Korean Neurological Association 2004;22(4):410-413
Sjogren's syndrome is a slowly progressive autoimmune disorder that predominantly affects major exocrine glands, and may also involve the central nervous system (CNS). It is sometimes very difficult to differentiate the CNS Sjogren's syndrome from multiple sclerosis. Here, we report two cases of Sjogren's syndrome who developed variable neurological symptoms mimicking the relapsing-remitting form of multiple sclerosis. There had been several relapses during the course of interferon-beta treatment but no relapses have occurred after steroid maintenance therapy.
Central Nervous System
;
Exocrine Glands
;
Interferon-beta
;
Multiple Sclerosis
;
Multiple Sclerosis, Relapsing-Remitting*
;
Recurrence
;
Sjogren's Syndrome*

Result Analysis
Print
Save
E-mail